|   |  |   |  | 
                    
                        |  |  
                        | 
                                
                                    | Home > 
                                        Products
                                        >  Human Cancer Cell Line Lysates |  
                                    | 
                                            
                                                
                                                    |  |  
                                                    | Human Cancer Cell Line Lysates |  
                                                    | 
	
	| American Kife Sciences ReadyLysates™ are ready-to-use Protein Lysates 
		supplied from human, mouse or rat Tissues and Cell Lines.  Ready Lysates™ are prepared by 
		grinding tissues or cell lines in either RIPA Buffer or SDS-lysis buffer in the presence 
		of various protease inhibitors.  After lysis the samples are centrifuged to remove cell 
		debris.   Ready Lysates™ from Tissues or Cell Lines are supplied in 1x SDS lysis buffer 
		with or without dye for immediate loading on poly acryl amide gels or immuno precipitation 
		and ELISA usages, respectively. Applications  Electrophoresis, Western blotting, and immuno precipitation 
			Protein-protein interaction analysis  
			 Tissue specific expression identification 
		
 |  | Ordering Information |  | 
		| Tissue Types | Catalog Number | Size | Price | 
|---|
 | Breast Cancer MCF-7 Cells | 1011 | 200 µg | $195 |  | Breast Cancer BT20 Cells | 1012 | 200 µg | $195 |  | Breast Cancer ZR75 Cells | 1013 | 200 µg | $195 |  | Breast Cancer T-47D Cells | 1014 | 200 µg | $195 |  | Prostate Cancer PC-3 Cells | 1015 | 200 µg | $195 |  | Prostate Cancer LNCap Cells | 1016 | 200 µg | $195 |  | Colon Cancer HT-29 Cells | 1016 | 200 µg | $195 |  | Colon Cancer LS 180 Cells | 1017 | 200 µg | $195 |  | Colon Cancer Colo 205 Cells | 1018 | 200 µg | $195 |  | Ovarian Cancer OV90 Cells | 1019 | 200 µg | $195 |  | HeLa Cells | 1020 | 200 µg | $195 |  |  |  |  |  |   |